

1. Record Nr.	UNINA9910985685403321
Titolo	Marcus and Feldman's osteoporosis / edited by David W. Dempster, Jane A. Cauley, Mary L. Bouxsein, Felicia Cosman
Pubbl/distr/stampa	London, United Kingdom : , : Elsevier/Academic Press, , [2021] ©2021
ISBN	0-12-813073-3
Edizione	[Fifth edition.]
Descrizione fisica	1 online resource (2 volumes) : illustrations
Soggetti	Osteoporosis Fractures, Bone - pathology Osteoporosis - therapy
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Revised edition of: Osteoporosis / edited by Robert Marcus, David Feldman, David W. Dempster, Marjorie Luckey, Jane A. Cauley. Fourth edition. 2013.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	-- Volume 1. Part I. Introduction. The nature of osteoporosis -- The bone organ system: form and function -- Part II. Developmental, cellular and molecular biology of bone. Development of the skeleton -- The skeletal stem cell -- Osteoclast biology -- Osteoblast biology: developmental origin and interactive nature of osteoblasts -- Osteocytes -- The regulatory role of matrix proteins in mineralization of bone -- Part III. Skeletal hormones and regulatory factors. Parathyroid hormone and parathyroid hormone-related protein -- Phosphatonins -- Skeletal growth factors -- WNT signaling in skeletal homeostasis and diseases -- Part IV. Biomechanics and mechanobiology. The mechanical behavior of bone -- Cellular and molecular mechanotransduction in bone -- Adaptation of skeletal structure to mechanical loading -- Biomechanics of hip and vertebral fractures -- Part V. Epidemiology of osteoporosis. Epidemiologic methods in studies of osteoporosis -- Genetics of osteoporosis -- Race, ethnicity, and osteoporosis -- Geographic variability in the incidence of hip and vertebral fractures -- Nutrition and osteoporosis -- Physical activity, exercise and skeletal health -- Reproductive and hormonal factors and the risk for osteoporosis -- Clinical and

epidemiological studies: skeletal changes across menopause -- Osteoporosis in men: what is similar and what is different? -- Falls as risk factors for fracture -- Impact of physical characteristics and lifestyle factors on bone density and fractures -- Imminent fracture risk and disability post fracture -- Economics of osteoporosis -- Part VI. General pathophysiology of osteoporosis. Skeletal heterogeneity and the purposes of bone remodeling -- On the evolution and contemporary roles of bone remodeling -- Estrogen deficiency and the pathogenesis of osteoporosis -- Cytokines and the pathogenesis of osteoporosis -- Bone and fat -- Bone, muscle, and sarcopenia -- Bone mineral acquisition in utero and during infancy and childhood -- Osteoporosis in childhood and adolescence -- Osteoporosis in premenopausal women, pregnancy, and lactation -- Bone and the microbiome -- Volume 2. Part VII. Impact of comorbidity and medications on skeletal health. Immobilization osteoporosis -- Osteoporosis in neurological disorders: Parkinson's disease, stroke, and multiple sclerosis -- Effects on the skeleton from medications used to treat non-skeletal disorders -- Osteoporosis associated with gastrointestinal disorders; celiac and inflammatory bowel diseases -- Osteoporosis associated with eating disorders -- Glucocorticoid-induced osteoporosis and Cushing's syndrome -- Thyroid hormone, thyroid medication, and the skeleton -- The skeletal actions of parathyroid hormone in primary hyperparathyroidism -- Osteogenesis imperfecta and other defects of bone development as occasional causes of adult osteoporosis -- Human immunodeficiency virus and osteoporosis -- Diabetes, diabetic medications, and risk of fracture -- Skeletal health after bariatric surgery -- Osteoporosis in organ transplant patients -- Osteoporosis associated with rheumatologic disorders -- Osteoporosis associated with chronic kidney disease -- Relationship between periodontal disease, tooth loss and osteoporosis -- Impact of breast cancer and its treatment on bone loss and fracture risk - pathophysiology and management -- Management of bone health in men with prostate cancer -- Impact of MGUS and myeloma on skeletal health -- Renal stone disease, hypercalciuria and osteoporosis: use of thiazides and alkali for osteoporosis -- Sleep disorders and osteoporosis -- Part VIII. Diagnosis and evaluation. Evaluation of the osteoporosis patient -- Who should be screened for osteoporosis? -- Vertebral fracture identification -- Noninvasive imaging techniques and fracture risk assessment -- Biochemical markers of bone turnover in osteoporosis -- A comparison of fracture risk assessment tools -- Part IX. Patient management. Orthopedic aspects of osteoporosis -- Fall prevention interventions -- Exercise and other physical therapy interventions in the management of osteoporosis -- Calcium and vitamin d in the management of osteoporosis -- Nutrients beyond calcium and vitamin d to treat osteoporosis -- Condition still critical: compliance and persistence with osteoporosis medications -- Part X. Pharmacotherapeutics. Estrogen and estrogen analogs for prevention and treatment of osteoporosis -- Bisphosphonates pharmacology and use in the treatment of osteoporosis -- Denosumab for the treatment of osteoporosis -- Teriparatide and abaloparatide treatment for osteoporosis -- Calcitonin in osteoporosis -- Androgens -- Long-term bisphosphonate treatment: continuation and interruption -- Romosozumab in the treatment of postmenopausal osteoporosis -- Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs -- Part XI. New directions. Long term treatment strategies and goal directed therapy.

editorial team, this fifth edition offers critical information on reproductive and hormonal risk factors, new therapeutics, ethnicity, nutrition, therapeutics, management and economics, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume reference is a must-have for biomedical researchers, research clinicians, fellows, academic and medical libraries, and any company involved in osteoporosis drug research and development.
